The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Wendy Stock and Anand Patel.
Wendy Stock
Connection Strength
4.843
Anand Patel
  1. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420.
    View in: PubMed
    Score: 0.690
  2. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
    View in: PubMed
    Score: 0.641
  3. Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma. Br J Haematol. 2026 Oct 15.
    View in: PubMed
    Score: 0.249
  4. Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment. Leukemia. 2026 Aug 31.
    View in: PubMed
    Score: 0.247
  5. Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
    View in: PubMed
    Score: 0.233
  6. Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis. Blood Cancer J. 2025 Oct 06; 15(1):158.
    View in: PubMed
    Score: 0.232
  7. Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
    View in: PubMed
    Score: 0.227
  8. CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
    View in: PubMed
    Score: 0.220
  9. Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650.
    View in: PubMed
    Score: 0.216
  10. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 05 01; 5(3):164-179.
    View in: PubMed
    Score: 0.210
  11. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
    View in: PubMed
    Score: 0.208
  12. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242.
    View in: PubMed
    Score: 0.205
  13. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
    View in: PubMed
    Score: 0.200
  14. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.188
  15. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.159
  16. Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
    View in: PubMed
    Score: 0.061
  17. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28.
    View in: PubMed
    Score: 0.061
  18. Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026 Feb 05; 147(6):639-649.
    View in: PubMed
    Score: 0.059
  19. Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456.
    View in: PubMed
    Score: 0.059
  20. Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia. Haematologica. 2026 Jul 01; 111(7):2466-2471.
    View in: PubMed
    Score: 0.059
  21. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 08 14; 15(1):138.
    View in: PubMed
    Score: 0.057
  22. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 11 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.055
  23. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
    View in: PubMed
    Score: 0.054
  24. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.051
  25. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043.
    View in: PubMed
    Score: 0.051
  26. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
    View in: PubMed
    Score: 0.051
  27. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.050
  28. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.